Reaction

Extravasation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,086 reports · 78 co-occurring drugs

As of the last recalculation, Extravasation appears in 4,086 FAERS reports alongside 78 co-occurring drug terms. The strongest observed disproportionality signal is IOHEXOL (PRR 84.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Iohexol	133	84.4	85.8
Iron Sucrose	149	82.6	83.9
Bendamustine Hydrochloride	93	40.5	40.8
Remdesivir	49	18.9	19.0
Alteplase	42	14.4	14.4
Norepinephrine Bitartrate	35	12.5	12.5
Ado-Trastuzumab Emtansine	20	12.1	12.2
Cetuximab	73	12.1	12.1
Norepinephrine	22	10.5	10.6
Propofol	67	9.5	9.5
Fluorouracil Cream, 0.5%	121	8.3	8.3
Fluorouracil	121	8.2	8.2
Oxaliplatin	108	7.6	7.6
Amiodarone Hydrochloride	16	7.3	7.3
Dextrose Monohydrate	19	7.3	7.3
Dextrose	18	7.0	7.0
Fosaprepitant Dimeglumine	18	6.7	6.7
Brentuximab Vedotin	13	6.5	6.5
Tranexamic Acid	11	6.3	6.3
Rocuronium Bromide	13	5.6	5.6
Calcium Gluconate	13	5.5	5.5
Bleomycin Sulfate	11	5.4	5.4
Aprepitant	19	5.3	5.3
Gentamicin	13	5.1	5.1
Doxorubicin Hydrochloride	32	5.0	5.0
Daratumumab	37	4.8	4.8
Carfilzomib	25	4.5	4.5
Sodium Chloride Tablet	61	4.3	4.3
Sodium Chloride Tablets	61	4.3	4.3
Sodium Chloride	65	4.2	4.2
Gentamicin Sulfate	13	4.2	4.2
Vancomycin Hydrochloride	53	4.1	4.1
Dexamethasone Sodium Phosphate	8	4.0	4.0
Doxorubicin	69	4.0	4.0
Piperacillin Sodium And Tazobactam Sodium	15	3.9	3.9
Basiliximab	9	3.9	3.9
Meropenem	24	3.8	3.8
Vancomycin	43	3.8	3.8
Linezolid	22	3.8	3.8
Etoposide	54	3.8	3.8
Durvalumab	15	3.8	3.8
Valganciclovir Hydrochloride Powder,	9	3.8	3.8
Cisplatin	53	3.5	3.5
Leucovorin Calcium	13	3.5	3.5
Paclitaxel (Aibumin-Bound)	55	3.4	3.4
Granisetron Hydrochloride	7	3.4	3.4
Granisetron	7	3.4	3.4
Bevacizumab	80	3.3	3.3
Agalsidase Beta	6	3.3	3.3
Paclitaxel	63	3.3	3.3
Bupivacaine	6	3.3	3.3
Anti-Thymocyte Globulin (Rabbit)	5	3.2	3.2
Zoledronic Acid	24	3.1	3.1
Fam-Trastuzumab Deruxtecan-Nxki	6	3.0	3.0
Carboplatin	74	3.0	3.0
Cyclophosphamide Injection, Solution	101	3.0	3.0
Cyclophosphamide	101	3.0	3.0
Cyclophosphamide For Injection	101	3.0	3.0
Nivolumab	53	2.8	2.8
Irinotecan Hydrochloride	7	2.8	2.8
Docetaxel Anhydrous	36	2.7	2.7
Docetaxel	36	2.7	2.7
Acyclovir	59	2.7	2.7
Gemcitabine	20	2.6	2.6
Mesna Injection	4	2.5	2.5
Trastuzumab	30	2.2	2.2
Ocrelizumab	27	2.2	2.2
Gemcitabine Hydrochloride	23	2.2	2.2
Obinutuzumab	7	2.2	2.2
Pertuzumab	11	2.1	2.1
Ipilimumab	17	2.0	2.0
Eculizumab	21	2.0	2.0
Lutetium Lu 177 Vipivotide Tetraxetan	5	1.9	1.9
Pemetrexed Disodium	14	1.9	1.9
Sevoflurane	3	1.8	1.8
Polatuzumab Vedotin	3	1.6	1.6
Paricalcitol	4	1.4	1.4
Pegfilgrastim	22	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.